SCHEMBL24766533

SCHEMBL24766533

Cc1cc(N2CCOCC2)nc(C(F)(F)F)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 3/20 0.58
KMT2A Q03164 4/20 0.50
CRHBP P24387 1/20 0.49
CRHR2 Q13324 1/20 0.49
TDP1 Q9NUW8 4/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
ATM Q13315 1/20 0.47
HTT P42858 1/20 0.45
KDM4E B2RXH2 6/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
ALDH1A1 P00352 2/20 0.44
HPGD P15428 2/20 0.44
HRH4 Q9H3N8 1/20 0.44
GAA P10253 1/20 0.44
PIK3CA P42336 1/20 0.44
MTOR P42345 1/20 0.44
TSHR P16473 3/20 0.43
HSD17B10 Q99714 3/20 0.43
MEN1 O00255 2/20 0.43
CYP1A2 P05177 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12110309 0.83 KMT2A (0.62) NPSR1KMT2ACRHBPCRHR2HTT
SCHEMBL24766278 0.83 NPSR1 (0.59) NPSR1KMT2ACRHBPCRHR2TDP1
SCHEMBL22488001 0.79 KMT2A (0.54) NPSR1KMT2ACRHBPCRHR2HTT
SCHEMBL970205 0.78 KMT2A (0.67) NPSR1KMT2ACRHBPCRHR2HTT
SCHEMBL23299953 0.77 KMT2A (0.56) NPSR1KMT2ACRHBPCRHR2HTT
SCHEMBL19805966 0.76 NPSR1 (0.55) NPSR1KMT2ACRHBPCRHR2TDP1
SCHEMBL29976432 0.76 NPSR1 (0.55) NPSR1KMT2ACRHBPCRHR2TDP1
SCHEMBL22121021 0.76 CRHBP (0.61) NPSR1KMT2ACRHBPCRHR2HTT
SCHEMBL13929505 0.76 HRH4 (0.68) NPSR1KMT2ACRHBPCRHR2KDM4E
SCHEMBL13173926 0.76 CYP1A2 (0.61) NPSR1KMT2ACRHBPCRHR2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11407737-B2 Inhibitors of RAF kinases KINNATE BIOPHARMA INC. (US) 2022-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11407737-B2 Inhibitors of RAF kinases BRAF, RAF1, ARAF NPSR1 4412/4885KMT2A 1631/4885CRHBP 4714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.